BRCA1 and breast carcinoma: Consequently, germline genetic screening for BRCA1/2 mutations has become an essential tool for cancer prediction and clinical management, enabling carriers to benefit from surveillance, chemoprevention, and preventive surgery to mitigate breast cancer risk [6].